ATROVENT Nebuliser solution

Active ingredients: Ipratropium

Product name and form

Atrovent 250 UDVs, 1 ml.

Atrovent UDVs, 2 ml.

Pharmaceutical Form

Nebuliser solution.

Qualitative and quantitative composition

Each single dose unit contains 0.025% w/v ipratropium bromide i.e. 250 micrograms in 1 ml and 500 micrograms in 2 ml.

For excipients, see 6.1.

Active Ingredient

Ipratropium is a quaternary ammonium compound with anticholinergic (parasympatholytic) properties. Ipratropium appears to inhibit vagally mediated reflexes by antagonising the action of acetylcholine, the transmitter agent released from the vagus nerve. Anticholinergics prevent the increase in intracellular concentration of Ca++, which is caused by interaction of acetylcholine with the muscarinic receptor on bronchial smooth muscle. Ca++ release is mediated by the second messenger system consisting of IP3 (inositol triphosphate) and DAG (diacylglycerol).

List of Excipients

Sodium chloride
1N Hydrochloric acid
Purified water

Pack sizes and marketing

Polyethylene unit dose vials containing either 1 ml or 2 ml of solution.

Pack sizes of 10, 20, 30, 50, 60, 80, 100, 120, 150, 200, 300, 500 and 1000.

Not all pack sizes may be marketed.

Marketing authorization holder

Boehringer Ingelheim Limited, Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS

Marketing authorization dates and numbers

PL 0015/0108

27 August 1986 / 23 December 2005


Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Ireland, Lithuania, Mexico, Netherlands, New Zealand, Poland, Singapore, Tunisia, United Kingdom, United States, South Africa